How much did In-Med Prognostics raise?

In-Med Prognostics raised $2.13 Million in a Seed round on December 12, 2022.

Neurological Healthcare Startup In-Med Prognostics Raises $2.13 Million In Funding Led By Exxora

PRIVATEDec 12, 2022

Amount Raised

$2.13 Million

Round Type

Seed

BiotechnologySoftwareHealth CareArtificial IntelligenceMachine LearningHealth Diagnostics

Description

AI-backed neurological healthcare startup In-Med Prognostics said Monday that it has raised $2.13 million in funding in a round led by Exxora, with participation from prominent angels.

Quick answer

In-Med Prognostics raised $2.13 Million in a Seed round, dated December 12, 2022.

How much did In-Med Prognostics raise?: In-Med Prognostics raised $2.13 Million in a Seed round on December 12, 2022.
What does In-Med Prognostics do?: We are a globally distributed health tech startup incubated in the GE Healthcare Edison Accelerator.

Source: Fundz verified event record.

Who else raised in Health Diagnostics and Biotechnology around the same time

Companies in the same sectors as In-Med Prognostics that raised within 45 days of this round, from Fundz verified event records.

Ibex Medical Analytics raised $10M (Funding Round) on November 9, 2022.
RegASK raised $10M (Series A) on December 15, 2022.
Carta Healthcare raised $20M (Series B) on November 2, 2022.
OpenLoop raised $368K (Seed) on December 28, 2022.
CodaMetrix raised $57M on December 16, 2022.
Perceiv AI raised an undisclosed amount on December 8, 2022.

Who to call at In-Med Prognostics, and when

A new round usually means In-Med Prognostics is about to hire and buy. The teams that reach out first get the meeting.

An alert the day In-Med Prognostics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at In-Med Prognostics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at In-Med Prognostics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

In-Med Prognostics

About

We are a globally distributed health tech startup incubated in the GE Healthcare Edison Accelerator. We are the first in the world to integrate data from multiple modalities for neurological health and provide ethnicity specific decision support insights for physicians and clinical researchers. Our proprietary software, Neuroshield™ integrates images, signal and text to produce automated, quantified reports to support the physician’s clinical impression for various neurological disorders. And it provides a seamless, end-to-end cloud-based image analysis platform for clinical and research use. Leveraging state-of-the-art data analytics and deep learning methodologies, we are developing a biomarker algorithm for various neurological disorders starting with epilepsy, dementia, Alzheimer’s Disease and Parkinson’s disease. In-Med was founded by Rajesh Purushottam, Dr. Latha Poonamallee & Dr. Al Curran.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment In-Med Prognostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Predictive Intelligence

Strategic

ML-powered predictions for In-Med Prognostics's next move

See what Strategic adds

In-Med Prognostics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.